Adrian Perdyan1, Piotr Spychalski2, Justyna Kacperczyk3, Olga Rostkowska2, Jarek Kobiela2. 1. Student Scientific Circle of Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdansk, Poland. Electronic address: perdyan.adrian@gumed.edu.pl. 2. Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdansk, Poland. 3. Students Scientific Society of General, Minimally Invasive and Elderly Surgery, Collegium Medicum of University of Warmia and Mazury, Poland.
Abstract
BACKGROUND: Liquid biopsy is a novel tool in oncology. It provides minimally invasive detection of tumor specific DNA. This review summarizes data on presence of circulating tumor DNA in serum or plasma of CRC patients as a potential negative prognostic factor. MATERIALS AND METHODS: The systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The search was performed using PubMed, Web of Science and Scopus. RESULTS: In total 18 articles with a total of 1779 patients met the inclusion criteria. Six out of 8 studies found that presence of ctDNA in plasma/serum was associated with inferior overall survival. All 6 studies found that high concentrations of ctDNA in plasma/serum was associated with inferior overall survival. CONCLUSIONS: Presence or high concentrations of KRAS mutation in plasma or serum were associated with inferior prognosis. Establishing cut-off concentrations is warranted for further clinical implementation of liquid biopsy.
BACKGROUND: Liquid biopsy is a novel tool in oncology. It provides minimally invasive detection of tumor specific DNA. This review summarizes data on presence of circulating tumor DNA in serum or plasma of CRC patients as a potential negative prognostic factor. MATERIALS AND METHODS: The systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The search was performed using PubMed, Web of Science and Scopus. RESULTS: In total 18 articles with a total of 1779 patients met the inclusion criteria. Six out of 8 studies found that presence of ctDNA in plasma/serum was associated with inferior overall survival. All 6 studies found that high concentrations of ctDNA in plasma/serum was associated with inferior overall survival. CONCLUSIONS: Presence or high concentrations of KRAS mutation in plasma or serum were associated with inferior prognosis. Establishing cut-off concentrations is warranted for further clinical implementation of liquid biopsy.
Authors: Wedad Saeed Al-Qahtani; Tahani Mohamed Al-Hazani; Fatmah Ahmed Safhi; Mashael Alhumaidi Alotaibi; Dalia Mostafa Domiaty; Salha M S Al-Shamrani; Eman Alshehri; Amani Mohammed Alotaibi; Saad Alkahtani Journal: Asian Pac J Cancer Prev Date: 2021-09-01